These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31711240)

  • 1. HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53.
    Capdevielle C; Desplat A; Charpentier J; Sagliocco F; Thiebaud P; Thézé N; Fédou S; Hooks KB; Silvestri R; Guyonnet-Duperat V; Petrel M; Raymond AA; Dupuy JW; Grosset CF; Hagedorn M
    Neuro Oncol; 2020 Apr; 22(4):550-562. PubMed ID: 31711240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas.
    Algranati D; Oren R; Dassa B; Fellus-Alyagor L; Plotnikov A; Barr H; Harmelin A; London N; Ron G; Furth N; Shema E
    Elife; 2024 Aug; 13():. PubMed ID: 39093942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
    Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
    Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scaffolding proteins in pediatric glioma.
    Capdevielle C; Hagedorn M
    Aging (Albany NY); 2021 Oct; 13(20):23440-23441. PubMed ID: 34705668
    [No Abstract]   [Full Text] [Related]  

  • 5. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
    Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
    Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
    Sears TK; Horbinski CM; Woolard KD
    J Neurooncol; 2021 Sep; 154(2):159-170. PubMed ID: 34424450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
    Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
    Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone acetyltransferase inhibitor II induces apoptosis in glioma cell lines via the p53 signaling pathway.
    Xu LX; Li ZH; Tao YF; Li RH; Fang F; Zhao H; Li G; Li YH; Wang J; Feng X; Pan J
    J Exp Clin Cancer Res; 2014 Dec; 33(1):108. PubMed ID: 25523932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.
    Lin GL; Wilson KM; Ceribelli M; Stanton BZ; Woo PJ; Kreimer S; Qin EY; Zhang X; Lennon J; Nagaraja S; Morris PJ; Quezada M; Gillespie SM; Duveau DY; Michalowski AM; Shinn P; Guha R; Ferrer M; Klumpp-Thomas C; Michael S; McKnight C; Minhas P; Itkin Z; Raabe EH; Chen L; Ghanem R; Geraghty AC; Ni L; Andreasson KI; Vitanza NA; Warren KE; Thomas CJ; Monje M
    Sci Transl Med; 2019 Nov; 11(519):. PubMed ID: 31748226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect.
    Rahal F; Capdevielle C; Rousseau B; Izotte J; Dupuy JW; Cappellen D; Chotard G; Ménard M; Charpentier J; Jecko V; Caumont C; Gimbert E; Grosset CF; Hagedorn M
    Neurooncol Adv; 2022; 4(1):vdac018. PubMed ID: 35300150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.
    Hennika T; Hu G; Olaciregui NG; Barton KL; Ehteda A; Chitranjan A; Chang C; Gifford AJ; Tsoli M; Ziegler DS; Carcaboso AM; Becher OJ
    PLoS One; 2017; 12(1):e0169485. PubMed ID: 28052119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
    Findlay IJ; De Iuliis GN; Duchatel RJ; Jackson ER; Vitanza NA; Cain JE; Waszak SM; Dun MD
    Oncogene; 2022 Jan; 41(4):461-475. PubMed ID: 34759345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
    Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
    PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHD2 Regulates Neuron-Glioma Interactions in Pediatric Glioma.
    Zhang X; Duan S; Apostolou PE; Wu X; Watanabe J; Gallitto M; Barron T; Taylor KR; Woo PJ; Hua X; Zhou H; Wei HJ; McQuillan N; Kang KD; Friedman GK; Canoll PD; Chang K; Wu CC; Hashizume R; Vakoc CR; Monje M; McKhann GM; Gogos JA; Zhang Z
    Cancer Discov; 2024 Sep; 14(9):1732-1754. PubMed ID: 38767413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
    Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
    BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
    Choi SA; Lee C; Kwak PA; Park CK; Wang KC; Phi JH; Lee JY; Chong S; Kim SK
    Cancer Lett; 2019 Feb; 442():161-169. PubMed ID: 30367915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.
    Chanchotisatien A; Pan J; Du Z; Qiu T; Yu J; Chu S
    World Neurosurg; 2019 Jul; 127():266-268. PubMed ID: 30981797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.